

References

1. Frishman WH, Pepine CJ, Weiss RJ, Baiker WM. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance in patients with angina taking extended-release nifedipine: results of multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *J Am Coll Cardiol* 1995;26:305-12.
2. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. *Am J Cardiol* 1986;57:437-97.
3. Buckberg GD, Fuder DE, Archie JP, Hofman JE. Experimental subendocardial ischemia in dogs with normal coronary arteries. *Circ Res* 1972;30:67-78.
4. Boudoulas H, Rittgers SE, Lewis RP, Leier CV, Weisler AM. Changes in diastolic time with various pharmacologic agents: implications for myocardial perfusion. *Circulation* 1979;60:164-9.
5. Ferro G, Spinelli L, Daibò C, Spadafora M, Guarnaccia F, Condorelli M. Diastolic perfusion time at ischemic threshold in patients with stress-induced ischemia. *Circulation* 1991;84:49-56.
6. Watanabe H, Ohtsuka S, Kakihama M, Sugishita Y. Coronary circulation in dogs with an experimental decrease in aortic compliance. *J Am Coll Cardiol* 1992;21:1497-506.
7. Stefanadis C, Wooley CF, Bush CA, Kolibash AJ, Boudoulas H. Aortic distensibility abnormalities in coronary artery disease. *Am J Cardiol* 1987;59:1300-4.
8. Boudoulas H, Gravanis MB. Ischemic heart disease. In: Gravanis MB, editor. Cardiovascular disorders pathogenesis and pathophysiology. St. Louis: Mosby-Year Book, 1993:14-63.
9. Psaty BM, Heckbert SR, Koopseil TD, et al. The use of myocardial infarction associated with antihypertensive drug therapies. *JAMA* 1995;274:620-5.

Reply

In response to Bouloulas and Leier, our findings with zatebradine do not just relate to a lack of an additive effect on exercise tolerance when the drug is administered to patients with angina pectoris already receiving nifedipine (1). There are reports showing that zatebradine is less effective than long-acting diltiazem on exercise tolerance when used as monotherapy (2) in patients with angina pectoris and no different from placebo in double-blind randomized trials (3). There are also data suggesting that zatebradine is less effective than propranolol in patients with angina pectoris despite similar reductions in heart rate. It is the combination of these clinical experiences that made us propose that negative inotropy or some metabolic protective action, or both, may be more important than heart rate reduction in the antianginal effects of rate-lowering calcium-entry and beta-adrenergic blocking agents (4). This is also suggested by the successful experience of Moss et al. (5) in using internal pacing to increase heart rate when using high dose beta-blockade to relieve symptoms in patients with refractory angina pectoris and bradycardia.

We did not evaluate diastolic time, systolic ejection time, collateral function or indexes of left ventricular function in our study and cannot respond to some of the specific remarks raised by Boudoulas and Leier.

WILLIAM H. FRISHMAN, MD, FACC
CARL J. PEPINE, MD, FACC
ROBERT J. WEISS, MD, FACC
WOLFGANG M. BAIKER, MD, FOR THE ZATEBRADINE
STUDY GROUP

Hospital of Albert Einstein College of Medicine
1825 Eastchester Road
Bronx, New York 10061

References

1. Frishman W, Pepine CJ, Weiss RJ, Baiker WM, for the Zatebradine Study Group. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina pectoris taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel group study. *J Am Coll Cardiol* 1995;26:305-12.
2. Waters D, Baird M, Marzotta C, et al. A randomized, double-blind, placebo-controlled trial of zatebradine and diltiazem SR in chronic stable angina: efficacy and safety [abstract]. *J Am Coll Cardiol* 1995;25:208A.
3. Glasser S. Selective reduction of heart rate with the sinus node inhibitor zatebradine (ULFS 49) does not lead to the expected improvements in exercise duration in patients with angina pectoris [abstract]. *J Am Coll Cardiol* 1995;25:127A.

4. Frishman WH, Gabor R, Pepine C, Cavusoglu E. Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor. *Am Heart J* 1996;131:204-10.
5. Moss AJ, Zareba W, Garcia E. Usefulness of implanted pacemakers in the management of patients with refractory angina pectoris and moderate bradycardia [abstract]. *Circulation* 1994;90:1171-604.

Dobutamine Stress Echocardiography in Orthotopic Heart Transplant Recipients

We read with great interest the report by Derumeaux et al. (1) on the evaluation of transplant coronary artery disease by dobutamine stress echocardiography. The authors deserve to be commended for using quantitative coronary angiography as the reference standard to compare the dobutamine stress echocardiographic findings. However, we would like to comment on the methods utilized to calculate sensitivity, specificity and positive and negative predictive values, which may have important implications on their findings. In their study (1), the authors used quantitative coronary angiography as the reference standard to evaluate the diagnostic accuracy of dobutamine stress echocardiography in 37 patients. They report a sensitivity and specificity of 86% and 91%, respectively. The problem is that these values (sensitivity, specificity, positive and negative predictive values) are not based on the comparative analysis of the results of dobutamine stress echocardiography versus those of quantitative coronary angiography. To derive the values the authors made two major assumptions: 1) Any inducible wall motion abnormality observed was attributable to the mere presence of focal epicardial coronary angiographic lesions rather than significant (>50%) lesions. 2) All focal epicardial coronary lesions were considered physiologically significant regardless of degree of stenosis. For example, in their study, seven patients with mild angiographic lesions (<40%) were considered to have true positive results solely on the basis of the positive results by dobutamine stress echocardiography. Obviously, this creates major problems in the analysis of sensitivity, specificity and positive and negative predictive accuracy. It is inconsistent to first use a test (quantitative coronary angiography in this case) as a reference standard to assess the accuracy of dobutamine stress test results and then later to incorporate insignificant coronary lesions as angiographically abnormal. For instance, when stress echocardiography results were positive in the presence of angiographic lesions as minimal as 15% stenosis, they were considered "true positive" in the calculation of sensitivity, specificity and positive and negative predictive values.

Without adhering to strict criteria based on quantitative angiography (reference standard), it may be difficult to know the false positive rate of dobutamine stress echocardiography in heart transplant recipients. Most investigators consider $\geq 50\%$ stenosis angiographically significant stenosis (2-5). The authors correctly point out the limitations of coronary angiography in assessing lesion severity in heart transplant recipients. Coronary angiography is known to underestimate the severity of underlying coronary artery disease in heart transplant recipients (6). However, at present, it is premature to consider dobutamine stress echocardiography the diagnostic test of choice for transplant coronary artery disease and as a substitute for coronary angiography as the reference standard.

Using standard criteria for defining significant coronary disease by nonquantitative coronary angiography, we derived the sensitivity and specificity in 41 transplant recipients (2). The sensitivity and specificity were 95% and 55%, respectively, and the negative and positive predictive values were 92% and 76%, respectively (2). In the current